A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
Celgene CC-900009-AML-001

To Learn More Call
201-510-0910

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Sponsor
Stemline

Protocol Number
Stemline Therapeutics STML-401-0314

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Sponsor
Astex

Protocol Number
Astex SGI-110-06

To Learn More Call
201-510-0910

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Site
Cape May Courthouse

Sponsor
Astellas

Protocol Number
Astellas 2215-CL-0201

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910